Connect Biopharma Holdings Ltd banner

Connect Biopharma Holdings Ltd
NASDAQ:CNTB

Watchlist Manager
Connect Biopharma Holdings Ltd Logo
Connect Biopharma Holdings Ltd
NASDAQ:CNTB
Watchlist
Price: 2.6 USD 5.26%
Market Cap: $145.3m

Wall Street
Price Targets

CNTB Price Targets Summary
Connect Biopharma Holdings Ltd

Wall Street analysts forecast CNTB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CNTB is 8.06 USD with a low forecast of 6.06 USD and a high forecast of 10.5 USD.

Lowest
Price Target
6.06 USD
133% Upside
Average
Price Target
8.06 USD
210% Upside
Highest
Price Target
10.5 USD
304% Upside
Connect Biopharma Holdings Ltd Competitors:
Price Targets
CDNA
CareDx Inc
21% Upside
TENB
Tenable Holdings Inc
58% Upside
BIOX
Bioceres Crop Solutions Corp
248% Upside

Revenue
Forecast

N/A
Past Growth
-2% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
-2% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

The compound annual growth rate of Connect Biopharma Holdings Ltd's revenue for the next 4 years is -2%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-43%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-43%
Average Miss

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-44%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-44%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CNTB's stock price target?
Price Target
8.06 USD

According to Wall Street analysts, the average 1-year price target for CNTB is 8.06 USD with a low forecast of 6.06 USD and a high forecast of 10.5 USD.

What is Connect Biopharma Holdings Ltd's Revenue forecast?
Projected CAGR
-2%

The compound annual growth rate of Connect Biopharma Holdings Ltd's revenue for the next 4 years is -2%.

Back to Top